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The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and the
anti-CD20 monoclonal antibody rituximab has been standard of care for diffuse large B-cell
lymphoma (DLBCL) since 2006, based on results from three randomized Phase III clinical trials:
GELA/LNH 98-5, Intergroup/E4494, and MInT (1–3). These trials showed that the addition of
rituximab to 6-8 cycles of anthracycline-based chemotherapy increased overall survival (OS) and
progression free (PFS) or event free survival (EFS) in both older patients (>60) with advanced-stage
DLBCL (GELA/LNH-98-5 and E4494), and younger patients (≤60) with favorable-risk disease,
deﬁned as stage II-IV with 0-1 International Prognostic Index (IPI) risk factors or bulky stage I
disease (MInT).
The MInT trial showed that 6 cycles of R-CHOP every 21 days (R-CHOP-21) are sufﬁcient in
younger DLBCL patients with favorable features and that patients with early-stage DLBCL (Ann
Arbor I and II) and no tumor bulk (variably deﬁned) had excellent outcomes without radiation
therapy (RT), making R-CHOP x 6 an alternative to R-CHOP x 3 + RT (3). A subset of patients
(N=101) with age-adjusted IPI 0 and disease bulk <7.5 cm had very favorable outcomes (PFS and
OS at 6 years 89.6% and 94.9%, respectively). Did this population actually need 6 cycles of R-CHOP?
Or could fewer cycles be sufﬁcient (without RT)? While the FLYER trial was not designed to directly
answer the RT question, it is relevant for RT decisions in clinical practice.
The FLYER trial was an international, randomized Phase III study conducted between December
2005 and October 2016 in the very favorable subset identiﬁed in the MInT trial, i.e. “young” patients
(age 18-60) with stage I/II (based on CT or PET/CT) untreated CD20-positive aggressive B-cell
lymphoma, without bulky disease, and with no age-adjusted IPI risk factors (4). The study enrolled
592 patients, of which 85% had DLBCL. Patients were randomized to receive R-CHOP every 21
days for 4 cycles, followed by an additional two doses of rituximab (n=297), or six cycles of R-CHOP
every 21 days (n=295). Radiation was planned only in patients with testicular involvement, as
prophylaxis to the contralateral testis.
The study asked whether a reduction in chemotherapy to 4 cycles would be non-inferior to
standard treatment with 6 cycles, with a non-inferiority margin of -5.5%. After median follow-up of
66 months, the study met its primary endpoint, with an absolute difference in 3-yr PFS of 3% (96%
with 4 cycles R-CHOP plus two doses of rituximab vs 94% with 6 cycles R-CHOP) and no difference
in 3-yr EFS or OS (89% vs 89% and 99% vs 98%, respectively). Forty patients progressed or relapsed.
Rates of relapse for patients with complete response (CR) or unconﬁrmed complete response (CRu),
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Molecular and biologic risk factors were not evaluated in the
FLYER trial. However, while cell of origin (COO) and double
expressor (DE)/double hit (DH) status are important prognostic
factors in advanced-stage DLBCL, the prognostic implication in
early-stage is unclear. Three retrospective studies provide some
data to address this question. One international study evaluated
192 patients with early-stage DLBCL treated with R-CHOP-like
regimens with or without RT (10). Of these patients, 60% were
classiﬁed as GCB and 40% as non-GCB. The total cohort had
excellent outcomes with 4-year PFS 85% and 4-year OS 88%, and
COO status did not inﬂuence outcomes. This study also
evaluated outcomes related to DE/DH status. Although limited
numbers, DE (32 patients) and DH (6 patients) status was not
associated with inferior PFS or OS. An additional retrospective
analysis evaluated the impact of COO on outcomes in 87 patients
with early-stage DLBCL treated with R-CHOP 3-4 cycles
plus RT (11). Most patients (75%) had GCB phenotype, and
IPI was similar between GCB and non-GCB groups. Again, no
signiﬁcant difference in PFS or OS between the two phenotypes
was found. More recently, a US multicenter retrospective study
evaluated outcomes in 104 patients with MYC-rearranged earlystage DLBCL (including 40 patients with DH) treated with
standard R-CHOP vs more intensive immunochemotherapy
(IIC = R-DA-EPOCH, R-HyperCVAD/MA, or R-CODOXM/IVAC) +/- RT. The 2-year PFS and OS were 78% and 86%
for the entire cohort, and 74% and 81% for the DH patients,
respectively. PFS and OS were similar across treatment groups
in the entire cohort and in patients with DH, noting that
the addition of consolidative RT yielded a higher CR rate.
Furthermore, the ORR in DH patients was comparable
between regimens (12). These studies suggest that COO and
DE/DH status may not have signiﬁcant prognostic implications
in early-stage DLBCL. Therefore, the lack of molecular and COO
data in FLYER should not affect the ﬁnal conclusions of
the study.

based on the 1999 consensus criteria (5), were similar, with no
CNS relapses. About two thirds of relapses occurred after 2 years.
Fewer adverse events occurred in the reduced chemotherapy
group. The rate of secondary neoplasm was similar. Does the
FLYER study give us justiﬁcation to use 4 cycles of R-CHOP, as
opposed to 6 (as in MInT) for these patients? An important
question that the FLYER study did not directly address is: can we
treat some patients with early-stage DLBCL with chemotherapy
only, omitting radiation?

POINT
The FLYER trial presents an improved treatment approach for
younger patients with early-stage favorable risk DLBCL,
decreasing toxicity through radiation omission and abbreviation
of chemotherapy.
Prior to this trial, the addition of involved ﬁeld RT to
chemotherapy, or combined-modality therapy (CMT), was
employed to allow for abbreviated chemotherapy in early-stage
DLBCL. The phase III SWOG 8736 trial initially examined CMT
in early-stage disease (6). Patients were randomized to 3 cycles
CHOP followed by RT (40-55 Gy to all visible sites of disease)
versus 8 cycles CHOP alone. Signiﬁcant improvement in 4-year
PFS (77% vs 64%) and OS (82% vs 72%) in favor of CMT was
shown. This led to the widespread adoption of CMT for patients
with early-stage DLBCL. The subsequent SWOG 0014 trial, a
single arm phase II trial, conﬁrmed excellent outcomes with
CMT for early-stage DLBCL in the rituximab era (7).
Others evaluated radiation omission in early-stage DLBCL.
The GELA LNH-93-4 trial examined abbreviated chemotherapy
without RT in the pre-rituximab era. Patients with early-stage
DLBCL and no adverse IPI risk factors were randomized to 4
cycles CHOP followed by RT versus 4 cycles CHOP alone (1).
There was no difference in 5-year EFS or OS between the two
groups. Notably, patients were >60 years old, a population
excluded from FLYER. In the rituximab era, LYSA/GOELAM
02-03 randomized patients age 18-75 years with stage I/II nonbulky (<7 cm) disease to receive RT versus no RT if interim PET/
CT (iPET) following 4 cycles R-CHOP showed CR (88% of
patients) (8). Patients received a total of 4 (n=187) or 6 cycles
(n=148) based on the presence of IPI risk factors. Notably, RCHOP was given every 14 days. For patients with CR on iPET, 5year EFS and OS were similar between patients who received
CMT versus chemoimmunotherapy alone. Collectively, these
trials support RT omission and chemotherapy abbreviation
early-stage DLBCL.
Recently, the S1001 trial evaluated a response-adaptive
strategy in patients with early-stage DLBCL (9). In this phase
II study, 132 eligible patients with early-stage, nonbulky
(<10 cm) disease received 3 cycles R-CHOP followed by iPET.
If iPET negative, patients received 1 additional cycle R-CHOP
for 4 cycles total. If iPET positive, they received RT followed by
ibritumomab tiuxetan, an anti-CD20 radioimmunoconjugate. In
128 iPET-evaluable patients, the 5-year PFS and OS were
excellent in both iPET-pos (N=14) and iPET-neg (N=114)
patients at 86% vs. 89% and 85% vs. 91%, respectively.

Frontiers in Oncology | www.frontiersin.org

COUNTERPOINT
For patients with early-stage, low-risk DLBCL, 3 cycles R-CHOP
followed by involved ﬁeld RT is an established and widely used
therapeutic option to reduce chemotherapy exposure and
toxicity. Avoidance of radiation and its associated toxicities is
an arguable beneﬁt of the FLYER trial; however, it is important to
accurately assess this risk in modern times. While the location of
the nodal disease dictates potential toxicities, current techniques
allow for reﬁned ﬁelds of radiation and reduction in dose,
minimizing short-term toxicities such as mucositis and
cytopenias. Data regarding long-term toxicities, including
secondary malignancy, infertility, and cardiac dysfunction, is
often extrapolated from Hodgkin lymphoma (HL) given the
higher utilization rates of RT. Patients with HL are typically
younger at diagnosis with more life-years for development of a
secondary malignancy, and often receive mediastinal radiation.
This is in contrast to the older population of DLBCL (median age
66 years) with smaller radiation ﬁelds often excluding major
organ systems. That being said, there are special circumstances
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that must be considered on an individual basis in which radiation
should be avoided, such as young female patients with inguinal
nodal disease to preserve fertility as well as breast and
mediastinal involvement of lymphoma.
The effect of COO and high-risk molecular features in earlystage disease is inconclusive and limited to retrospective studies.
Several studies as described above found no different between
subtypes. An additional retrospective review of 151 patients with
early-stage disease evaluated COO in patients who received RCHOP with or without RT (13). COO was determined in 87
patients, with 62 GCB and 25 non-GCB. Excellent responses were
observed in both therapeutic groups as expected. However, analysis
of COO impact showed that non-GCB was associated with inferior
5-year PFS and OS (73.9% and 59.7%) compared to GCB (95.9%
and 90.6%). The trend of inferior outcome was more pronounced in
non-GCB receiving 4 cycles or less of R-CHOP regardless of RT.
The authors of the FLYER trial plan to report biologic risk factors in
their population of patients, a necessary analysis to support the
safety of abbreviated therapy across all subtypes.
Long-term follow up from both the SWOG 8736 and SWOG
0014 trials shows a continued pattern of late relapses in early-stage
DLBCL, suggesting that CMT and rituximab may not mitigate risk
of long term relapse in this population (7, 14). This pattern was
again observed in the FLYER study. While relapse rates after CR or
unconﬁrmed CR were low at 4-5%, the majority of relapses were
observed after 2 years, with the cumulative incidence of relapse
demonstrating a linear trend during years 3 to 6 of follow-up. So,
while the approach of abbreviated chemotherapy was demonstrated
to be non-inferior to a longer course of chemotherapy, the issue of
late relapse in this early-stage, favorable-risk population remains.
The extended recruitment period (11 years) should be noted
and was recognized by the authors. This prolonged recruitment
time is likely reﬂective of the low incidence of early-stage, lowrisk DLBCL and of DLBCL in younger patients in general. While
DLBCL is the most common type of non-Hodgkin lymphoma,
only approximately 30% of patients present with stage I/II
disease by PET scan (15). The median age at diagnosis is 66
years, with most patients being diagnosed between ages 65-74
years; this older population was not included in this trial (16).
While the ﬁndings of this study are certainly applicable to the
patient population evaluated, they are not generalizable to
patients older than 60 which make for approximately 50% of
all patients with early-stage DLBCL (8, 9).

cycles of rituximab and still have the same excellent outcomes
with less toxicity? The answer, provided by the FLYER trial, is
yes. What the FLYER trial cannot tell us, because it was not
designed to, is whether 4 cycles R-CHOP are equivalent to 3-4
cycles R-CHOP plus RT, in this population. As discussed above,
evidence surrounding the use of RT in patients with early-stage
DLBCL is complex and should be parsed carefully, to ensure the
right conclusions are not applied to the wrong patients. To avoid
this fallacy, reviewing the speciﬁcs of each trial is essential.
Studies conducted in the pre-rituximab era (S8736 and GELA
LNH-93.4) have lost much of their relevance, not only given lack
of rituximab, but also because the diagnostic classiﬁcation of Bcell lymphoma has changed so dramatically that one cannot be
sure the same patients are evaluated in more recent studies (in
fact, S8736 likely included some T-cell lymphomas). Guessing
the impact of COO and molecular features on the outcomes
found in these trials is also difﬁcult, because this information was
not available when the trials began. Another issue is patient
selection based on deﬁnition of bulky disease, risk stratiﬁcation,
and age. The trials discussed above are inconsistent regarding
deﬁnition of “bulk” and eligibility, and conclusions are often
drawn from subset analyses of the entire cohort. Finally,
emerging data on the value of iPET in adapting treatment
selection post-hoc are gradually making a priori therapeutic
planning based on risk stratiﬁcation less relevant. Thus, NCTN
S001 and LYSA/GOELAM 02-03 data provide strong support for
a RT-free approach to early-stage DLBCL, for iPET-negative
patients, including patients older than 60, and those with tumor
bulk <10 cm. Of course, this raises the question of quality
assurance in PET interpretation, which remains inconsistent.
This is where the FLYER study is quite helpful, because it did not
have a PET-adapted design. In conclusion, most patients with
early-stage DLBCL can be treated with abbreviated R-CHOP
without radiation. Patients younger than 60, with tumors <7.5 cm,
and no IPI risk factors, can be treated with 4 cycles R-CHOP
without iPET, based on the FLYER trial. Patients older than 60,
with masses <10 cm, and some IPI risk factors, can be treated with
4 cycles R-CHOP if their iPET is negative. Long-term follow up is
necessary. The studies of CMT, both before and after rituximab,
suggest a pattern of late relapses, which could be due to a distinct
biology. Further characterization of the biologic and clinical
diversity of early-stage DLBCL is warranted.

AUTHOR CONTRIBUTIONS

DISCUSSION

KS and AM wrote and edited the manuscript. AB and PP
reviewed and edited the manuscript. All authors contributed to
the article and approved the submitted version.

The FLYER trial was built on the observation (from MInT) that a
subset of DLBCL patients with age ≤60, zero IPI risk factors, and
non-bulky disease have extraordinarily favorable outcomes, with
OS close to 95% when treated with 6 cycles R-CHOP-21.
Although a large fraction of these patients had early-stage
DLBCL and could have been treated with CMT, they received
the extended chemotherapy regimen, without radiation. This
observation raised the question: can patients with very favorable
DLBCL be treated with only 4 cycles R-CHOP +2 additional
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